Association of p73 G4C14-to-A4T14 polymorphism with non-small cell lung cancer risk

Association between p73 RS2273953 to RS1801173 polymorphism and risk of lung cancer: a meta-analysis of 2,897 cases and 3,317 controls

BACKGROUND

Lung cancer is one of the most common and deadly cancers in humans. P73, a member of the p53 family, is a vital gene for the carcinogenesis of lung cancer. Single nucleotide polymorphism (SNP) of P73 gene may affect the risk of lung cancer. Therefore, we performed a meta-analysis of p73 SNP and lung cancer risk using the most recent data.

METHODS

A total of 1407 articles from EMBASE, Web of science, PubMed and Chinese National Knowledge Infrastructure (CNKI) databases were identified initially from the search. A meta-analysis of the association between P73 polymorphism and lung cancer risk was performed based on various genetic models and by type of lung cancer and race.

RESULTS

Seven articles published in either English or Chinese with English abstract were eventually selected for final analysis. The total pooled population included 6214 subjects (2,897 cases and 3,317 controls). The results showed that p73 RS2273953 to RS1801173 polymorphism was associated with increased risk of lung cancer in Caucasians but not in Asians. Within Asians, those with p73 GC/GC may have an increased risk for squamous carcinoma compared to those with GC/AT+AT/AT polymorphism.

CONCLUSIONS

Our analysis suggested a lack of association between p73 RS2273953 to RS1801173 polymorphism and risk of lung cancer overall. However, patients with GC/GC polymorphism showed an increased risk for squamous carcinoma in the lung compared to those with GC/AT+AT/AT in Asians.

Association between TP73 G4C14-A4T14 polymorphism and different cancer types: an updated meta-analysis of 55 case-control studies

OBJECTIVE

The TP73 G4C14-A4T14 variant has been associated with elevated cancer risk, but the evidence is inconclusive. We performed a meta-analysis to clarify the role of this variant in cancer development.

METHODS

Eligible literature was selected by searching PubMed, Google Scholar, Cochrane Library, and Embase. The meta-analysis was performed using Review Manager 5.4.

RESULTS

A meta-analysis of 55 case-control studies showed that the G4C14-A4T14 variant was significantly associated with overall cancer development in five genetic models, including the allele model (AM), codominant model 1 (COD1), COD2, dominant model (DM), and over-dominant model (OD). Sub-group analysis based on ethnicity showed significantly higher risks in Africans in COD2 and RM and in Whites in AM, COD2, DM, and recessive model (RM). Cancer-specific subgroup analysis identified significant risks of gynecological (ovarian, cervical, and endometrial cancer), colorectal, oral, head and neck, and other cancers. Moreover, hospital-based controls revealed significant cancer risks in the AM, COD1, COD2, DM, and RM genetic models. Our findings were confirmed by trial sequential analysis.

CONCLUSION

This meta-analysis confirmed that TP73 G4C14-A4T14 significantly elevates the overall cancer risk, especially in White, African, and hospital-based populations, and specifically predisposes individuals to gynecological, colorectal, oral, and head and neck cancers.This meta-analysis was registered at INPLASY (registration number: INPLASY202210070).

Relationship of p73 gene polymorphism and additional gene-smoking and gene-obesity interaction with non-small cell lung cancer risk

Aim

The aim of this study was to investigate the impact of G4C14-to-A4T14 polymorphism within P73 gene and additional interactions with current smoking and obesity on non-small cell lung cancer (NSCLC) risk in a Chinese population.

Results

Logistic regression analysis showed a significant association between genotypes of the AT allele in G4C14-to-A4T14 and decreased NSCLC risk. NSCLC risk was significantly lower in carriers of the G4C14-to-A4T14- AT allele than those with GC/GC genotype (AT/AT + GC/AT versus GC/GC), adjusted OR (95%CI) = 0.68 (0.55–0.93). We also found that the OR (95%CI) was 1.88 (1.32-2.47) for current smokers compared with never smokers and 0.69 (0.40–0.95) for obese subjects compared to participants with normal BMI. Never smokers with AT/AT or GC/AT of the G4C14-to-A4T14 genotype have the lowest NSCLC risk compared with smokers with the GC/GC genotype after covariates adjustment, OR (95%CI) = 0.52 (0.26-0.87). Obese participants with G4C14-to-A4T14- AT/AT or GC/AT genotype have the lowest NSCLC risk compared with non- obese subjects with the GC/GC genotype after adjusting for covariates, OR (95% CI) = 0.56 (0.33–0.85).

Materials and Methods

A logistic regression model was used to examine the association between G4C14-to-A4T14 polymorphism and NSCLC, and its interaction with current smoking and obesity. The odds ratios (OR) and 95% confident intervals (95%CI) were calculated.

Conclusions

Our results support an important association between the G4C14-to-A4T14 and decreased NSCLC risk and additional impact of an interaction between G4C14-to-A4T14 and smoking or obesity on NSCLC risk.